Predicted protein targets (top 13)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | LRRK2 | Q5S007 | 4/20 | 0.53 |
| ▸ | ALK | Q9UM73 | 4/20 | 0.52 |
| ▸ | INSR | P06213 | 2/20 | 0.52 |
| ▸ | EGFR | P00533 | 6/20 | 0.52 |
| ▸ | BRD4 | O60885 | 4/20 | 0.49 |
| ▸ | BTK | Q06187 | 1/20 | 0.47 |
| ▸ | JAK2 | O60674 | 1/20 | 0.45 |
| ▸ | SRC | P12931 | 1/20 | 0.45 |
| ▸ | TNK2 | Q07912 | 1/20 | 0.45 |
| ▸ | PTK2 | Q05397 | 1/20 | 0.45 |
| ▸ | MAPK8 | P45983 | 1/20 | 0.45 |
| ▸ | MAPK9 | P45984 | 1/20 | 0.45 |
| ▸ | MAPK10 | P53779 | 1/20 | 0.45 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL18369605 | 0.88 | LRRK2 (0.51) | LRRK2ALKINSREGFR | |
| SCHEMBL17059187 | 0.85 | EGFR (0.55) | LRRK2ALKINSREGFRBRD4 | |
| SCHEMBL17059230 | 0.85 | ALK (0.50) | LRRK2ALKINSREGFRBRD4 | |
| SCHEMBL18359226 | 0.83 | EGFR (0.70) | ALKEGFR | |
| SCHEMBL17059198 | 0.79 | EGFR (0.52) | LRRK2ALKINSREGFR | |
| SCHEMBL17196875 | 0.77 | EGFR (0.51) | LRRK2ALKEGFRBRD4PTK2 | |
| SCHEMBL17059191 | 0.76 | LRRK2 (0.52) | LRRK2ALKINSREGFR | |
| SCHEMBL18369603 | 0.76 | EGFR (0.61) | EGFR | |
| SCHEMBL30939736 | 0.76 | EGFR (0.77) | LRRK2ALKINSREGFRMAPK8 | |
| SCHEMBL28938956 | 0.76 | MAPK9 (0.60) | LRRK2ALKINSREGFRBTK |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 5 patents. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-10435400-B2 | 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom | Shanghai Haiyan Pharmaceutical Technology Co. Ltd. (CN) | 2019-10-08 | — | — | US | disclosed |
| US-20170008889-A1 | 2,4-DISUBSTITUTED PHENYLENE-1,5-DIAMINE DERIVATIVES AND APPLICATIONS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM | Shanghai Haiyan Pharmaceutical Technology Co. Ltd. (CN) | 2017-01-12 | — | — | US | disclosed |
| US-20170008889-A1 | 2,4-DISUBSTITUTED PHENYLENE-1,5-DIAMINE DERIVATIVES AND APPLICATIONS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM | Shanghai Haiyan Pharmaceutical Technology Co. Ltd. (CN) | 2017-01-12 | — | — | US | disclosed |
| EP-3112364-A1 | 2,4-DISUBSTITUTED PHENYLENE-1,5-DIAMINE DERIVATIVES AND APPLICATIONS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM | Shanghai Haiyan Pharmaceutical Technology Co. Ltd. (CN) | 2017-01-04 | — | — | EP | disclosed |
| WO-2015127872-A1 | 2,4-DISUBSTITUTED PHENYLENE-1,5-DIAMINE DERIVATIVES AND APPLICATIONS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM | 上海海雁医药科技有限公司 | 2015-09-03 | — | — | WO | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20170008889-A1 | 2,4-DISUBSTITUTED PHENYLENE-1,5-DIAMINE DERIVATIVES AND APPLICATIONS THEREOF, AND PHARMACEUTICAL COMPOSITIONS AND PHARMACEUTICALLY ACCEPTABLE COMPOSITIONS PREPARED THEREFROM | ERBB2, EGFR, ERBB3 | LRRK2 2261/4885ALK 21/4885INSR 827/4885 |
| US-10435400-B2 | 2,4-disubstituted phenylene-1,5-diamine derivatives and applications thereof, and pharmaceutical compositions and pharmaceutically acceptable compositions prepared therefrom | ERBB2, EGFR, ERBB3 | LRRK2 2261/4885ALK 21/4885INSR 827/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.